Carregant...
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352566/ https://ncbi.nlm.nih.gov/pubmed/32560564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061607 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|